- Home
- ONCO vs XRTX Comparison
ONCO vs XRTX Comparison
Compare ONCO & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- XRTX
- Stock Information
- Founded
- ONCO 2018
- XRTX 2011
- Country
- ONCO United States
- XRTX Canada
- Employees
- ONCO N/A
- XRTX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- ONCO Health Care
- XRTX Health Care
- Exchange
- ONCO Nasdaq
- XRTX Nasdaq
- Market Cap
- ONCO 4.7M
- XRTX 4.4M
- IPO Year
- ONCO 2022
- XRTX N/A
- Fundamental
- Price
- ONCO $3.79
- XRTX $0.63
- Analyst Decision
- ONCO
- XRTX
- Analyst Count
- ONCO 0
- XRTX 0
- Target Price
- ONCO N/A
- XRTX N/A
- AVG Volume (30 Days)
- ONCO 65.4K
- XRTX 6.0M
- Earning Date
- ONCO 12-09-2025
- XRTX 11-14-2025
- Dividend Yield
- ONCO N/A
- XRTX N/A
- EPS Growth
- ONCO N/A
- XRTX N/A
- EPS
- ONCO N/A
- XRTX N/A
- Revenue
- ONCO $1,326,959.00
- XRTX N/A
- Revenue This Year
- ONCO N/A
- XRTX N/A
- Revenue Next Year
- ONCO N/A
- XRTX N/A
- P/E Ratio
- ONCO N/A
- XRTX N/A
- Revenue Growth
- ONCO N/A
- XRTX N/A
- 52 Week Low
- ONCO $2.45
- XRTX $0.62
- 52 Week High
- ONCO $305.15
- XRTX $1.79
- Technical
- Relative Strength Index (RSI)
- ONCO 55.84
- XRTX 39.13
- Support Level
- ONCO $3.48
- XRTX $0.62
- Resistance Level
- ONCO $3.65
- XRTX $0.73
- Average True Range (ATR)
- ONCO 0.21
- XRTX 0.09
- MACD
- ONCO -0.01
- XRTX -0.02
- Stochastic Oscillator
- ONCO 39.18
- XRTX 2.74
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.